The Duration of Gonadotropin Stimulation Does Not Alter the Clinical Pregnancy Rate in IVF or ICSI Cycles

Overview

Journal Ir J Med Sci

Specialty General Medicine

Date 2016 Nov 9

PMID 27822908

Citations 2

Authors

N Purandare

G Emerson

C Kirkham

C Harrity

D Walsh

E Mocanu

Affiliations

Soon will be listed here.

Abstract

Background: Ovarian stimulation is an essential part of assisted reproduction treatments. Research on whether the duration of stimulation alters the success in assisted reproduction has not been conclusive.

Aim: The purpose of the study was to establish whether the duration of ovarian stimulation alters the success in assisted reproduction treatments.

Methods: All fresh (non-donor) stimulation cycles performed in an academic tertiary referral ART centre over a period of 18 years, between 1st January 1997 and 31st December 2014, were identified. Data were prospectively and electronically collected. IVF and ICSI cycles were analysed independently. Each category was then subdivided into assisted reproduction cycles where the antagonist, long (down regulation) and flare protocol were used. Clinical pregnancy was the main outcome measured. A total of 10,478 stimulation cycles (6011 fresh IVF and 4467 fresh ICSI) reaching egg collection were included.

Results: We showed no significant difference in CP rates in IVF cycles for the long (p = 0.082), antagonist (p = 0.217) or flare (p = 0.741) protocol cycles or in ICSI cycles with the long (p = 0.223), antagonist (p = 0.766) or the flare (p = 0.690) protocol with regards the duration of stimulation.

Conclusion: The duration of stimulation does not alter the CP rate in ICSI or IVF cycles using the long, antagonist or flare stimulation protocol.

Citing Articles

Conventional ovarian stimulation vs. delayed single dose corifollitropin alfa ovarian stimulation in oocyte donors: a prospective randomized study. Tail trial.

Alvarado Franco C, Bernabeu Garcia A, Sunol Sala J, Guerrero Villena J, Albero Amoros S, Llacer J Front Reprod Health. 2023; 5:1239175.

PMID: 37965590 PMC: 10642283. DOI: 10.3389/frph.2023.1239175.

Association Between the Ratio of Ovarian Stimulation Duration to Original Follicular Phase Length and Fertilization Outcomes: A Novel Index to Optimise Clinical Trigger Time.

Zhao X, Zhang X, Wu S, Tan J Front Endocrinol (Lausanne). 2022; 13:862500.

PMID: 35957813 PMC: 9361069. DOI: 10.3389/fendo.2022.862500.

References

Youssef M, Abdelmoty H, Ahmed M, Elmohamady M . GnRH agonist for final oocyte maturation in GnRH antagonist co-treated IVF/ICSI treatment cycles: Systematic review and meta-analysis. J Adv Res. 2015; 6(3):341-9. PMC: 4522577. DOI: 10.1016/j.jare.2015.01.005. View

Chen S, Sun L, Kong L, Li L, Li J, Zhu L . [Clinical outcome of patients with follicular development retardation by prolonged duration of gonadotropin administration for in vitro fertilization]. Zhonghua Fu Chan Ke Za Zhi. 2007; 42(8):526-9. View

Chuang M, Zapantis A, Taylor M, Jindal S, Neal-Perry G, Lieman H . Prolonged gonadotropin stimulation is associated with decreased ART success. J Assist Reprod Genet. 2010; 27(12):711-7. PMC: 2997954. DOI: 10.1007/s10815-010-9476-6. View

Baker V, Luke B, Brown M, Alvero R, Frattarelli J, Usadi R . Multivariate analysis of factors affecting probability of pregnancy and live birth with in vitro fertilization: an analysis of the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System. Fertil Steril. 2009; 94(4):1410-1416. DOI: 10.1016/j.fertnstert.2009.07.986. View

Samara N, Reis D, Miller N, Ghetler Y, Berkovitz A, Miller M . What are the best predictors for successful GnRH antagonist protocol in in vitro fertilization (IVF) treatment?. Gynecol Endocrinol. 2015; 31(11):877-9. DOI: 10.3109/09513590.2015.1081680. View

Huang J, Rosenwaks Z . In vitro fertilisation treatment and factors affecting success. Best Pract Res Clin Obstet Gynaecol. 2012; 26(6):777-88. DOI: 10.1016/j.bpobgyn.2012.08.017. View

Bonilla-Musoles F, Castillo J, Caballero O, Perez-Panades J, Bonilla Jr F, Dolz M . Predicting ovarian reserve and reproductive outcome using antimüllerian hormone (AMH) and antral follicle count (AFC) in patients with previous assisted reproduction technique (ART) failure. Clin Exp Obstet Gynecol. 2012; 39(1):13-8. View

Martin J, Nisker J, Tummon I, Daniel S, Auckland J, Feyles V . Future in vitro fertilization pregnancy potential of women with variably elevated day 3 follicle-stimulating hormone levels. Fertil Steril. 1996; 65(6):1238-40. DOI: 10.1016/s0015-0282(16)58347-2. View

Hock D, Louie H, Shelden R, Ananth C, Kemmann E . The need to step up the gonadotropin dosage in the stimulation phase of IVF treatment predicts a poor outcome. J Assist Reprod Genet. 1998; 15(7):427-30. PMC: 3454803. DOI: 10.1007/BF02744936. View

10.

Maheshwari A, Stofberg L, Bhattacharya S . Effect of overweight and obesity on assisted reproductive technology--a systematic review. Hum Reprod Update. 2007; 13(5):433-44. DOI: 10.1093/humupd/dmm017. View

11.

Martin J, Mahutte N, Arici A, Sakkas D . Impact of duration and dose of gonadotrophins on IVF outcomes. Reprod Biomed Online. 2006; 13(5):645-50. DOI: 10.1016/s1472-6483(10)60654-2. View

12.

Ryan A, Wang S, Alvero R, Polotsky A . Prolonged gonadotropin stimulation for assisted reproductive technology cycles is associated with decreased pregnancy rates for all women except for women with polycystic ovary syndrome. J Assist Reprod Genet. 2014; 31(7):837-42. PMC: 4096873. DOI: 10.1007/s10815-014-0253-9. View

13.

Mardesic T, Mannaerts B, Abuzeid M, Levy M, Witjes H, Fauser B . Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective analysis of the Engage trial. Reprod Biomed Online. 2014; 28(4):462-8. DOI: 10.1016/j.rbmo.2013.12.009. View